Mary Koshy, John Kauh, Clifford Gunthel, Melissa Joyner, Jerome Landry, Charles R Thomas
{"title":"最新进展:人类免疫缺陷病毒(HIV)人群中的胃肠道恶性肿瘤","authors":"Mary Koshy, John Kauh, Clifford Gunthel, Melissa Joyner, Jerome Landry, Charles R Thomas","doi":"10.1385/IJGC:36:1:001","DOIUrl":null,"url":null,"abstract":"<p><p>The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral therapy (HAART). The following is a concise review summarizing the current state-of-the-art for GI tract malignancies in the HIV-positive patient and is designed to assist the clinical oncology team in developing a rationale plan when caring for these patients.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"36 1","pages":"1-14"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:36:1:001","citationCount":"6","resultStr":"{\"title\":\"State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.\",\"authors\":\"Mary Koshy, John Kauh, Clifford Gunthel, Melissa Joyner, Jerome Landry, Charles R Thomas\",\"doi\":\"10.1385/IJGC:36:1:001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral therapy (HAART). The following is a concise review summarizing the current state-of-the-art for GI tract malignancies in the HIV-positive patient and is designed to assist the clinical oncology team in developing a rationale plan when caring for these patients.</p>\",\"PeriodicalId\":84927,\"journal\":{\"name\":\"International journal of gastrointestinal cancer\",\"volume\":\"36 1\",\"pages\":\"1-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1385/IJGC:36:1:001\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of gastrointestinal cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1385/IJGC:36:1:001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of gastrointestinal cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1385/IJGC:36:1:001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.
The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral therapy (HAART). The following is a concise review summarizing the current state-of-the-art for GI tract malignancies in the HIV-positive patient and is designed to assist the clinical oncology team in developing a rationale plan when caring for these patients.